research use only

BEC HCl Arginase inhibitor

Name: BEC HCl
Brand: Selleck Chemicals
SKU: S7929
Rating: 5 (4 reviews)

Cat.No.S7929

BEC HCl is a slow-binding, and competitive arginase inhibitor with K_i of 0.31 μM (pH7.5) and 0.4-0.6 μM for Arginase II and rat Arginase I, respectively.

Chemical Structure

Molecular Weight: 229.49

Jump to

Quality Control

Batch: S792901 DMSO]45 mg/mL]false]Water]45 mg/mL]false]Ethanol]45 mg/mL]false Purity: 99.89%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

99.89

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other Arginase Inhibitors	DL-Norvaline Nor-NOHA Acetate Arginase inhibitor 1

Chemical Information, Storage & Stability

Molecular Weight	229.49	Formula	C₅H₁₂BNO₄S.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	222638-67-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	B(CCSCC(C(=O)O)N)(O)O.Cl

Solubility

In vitro
Batch:

DMSO : 45 mg/mL (196.08 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 45 mg/mL

Ethanol : 45 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.250mg/ml (9.80mM)	Taking the 1 mL working solution as an example, add 50 μL of 45 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.560mg/ml (2.44mM)	Taking the 1 mL working solution as an example, add 50 μL of 11.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Arginase II 0.31 μM(Ki) rat Arginase I <0.6 μM(Ki)
In vitro	BEC causes significant enhancement of NO-dependent smooth muscle relaxation. In myocytes, BEC augments Ca(2+)-dependent NOS activity and NO production, and increases basal contractility. BEC also inhibits the proliferation of human pulmonary artery smooth muscle cells by decreasing the expression levels of cyclin D1 and CDK4, increasing the expression of p27, and partly reducing the phosphorylation of Akt and ERK.
In vivo	In mice with allergic inflammation (OVA/OVA), BEC enhances peribronchiolar and perivascular inflammation, leads to enhanced NF-κB DNA binding and NF-κB-dependent inflammatory gene expression, and causes an increase in the content of NOx. In rats with pulmonary arterial hypertension, BEC reduces the right ventricle systolic pressure.
References	[1] https://pubmed.ncbi.nlm.nih.gov/11478904/ [2] https://pubmed.ncbi.nlm.nih.gov/11258879/ [3] https://pubmed.ncbi.nlm.nih.gov/16537391/ [4] https://pubmed.ncbi.nlm.nih.gov/18768883/ [5] https://pubmed.ncbi.nlm.nih.gov/26126810/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):